Press Ventures and Biosafety Systems Sp z.o. Expand Into European Market With New Corporate Headquarters
September 04 2013 - 2:54PM
Press Ventures Inc. (OTCQB:PVEN) ("Press Ventures" or the
"Company"), is pleased to announce that the Company has formed a
new wholly-owned European subsidiary and established a new European
Union (EU) corporate headquarters.
With the recently announced addition of our new CEO, it made
strong business sense to have a new corporate focus in the EU where
Mr. Denkiewicz's extensive business contacts and vast experience
will enhance the Company's efforts to bring its product to the
marketplace rapidly. There is strong support within the EU for
"natural" biosafety solutions for the food and commercial building
sectors. The Company feels that EU business development is a very
important opportunity for its patented Cedar Leaf Oil Diffusion
("CLO-D") technology.
"Through our research, we have come to believe that the EU
represents an enormous multi-billion dollar market opportunity for
our patented cedar oil biosafety system, the Company, and its
shareholders," stated Mr. Edward Denkiewicz, CEO of Press Ventures
and BioSafety Solutions Inc., a wholly owned subsidiary of the
Company. "There is a global movement away from the use of harmful
chemicals in our lives and our all-natural biosafety solution has
been proven to be 100% safe, while still effectively eradicating
dangerous bacteria and viruses from affecting humans. The opening
of this new corporate headquarters in Warsaw, Poland is a truly
exciting step forward for the Company and will form a base of
operations in the center of what we feel will be one of our main
global markets."
Traditionally, Europeans have shown a strong resistance to
dangerous chemical biosafety solutions that can negatively affect
human health. The potential EU market targeted for the Company's
patented Cedar Leaf Oil Diffusion ("CLO-D") technology is estimated
at over $28 billion to target bacteria and viruses in food
processing facilities alone. The Company will also target another
potential multi-billion market opportunity in hospital biosafety.
Hospitals are constantly fighting the spread of infectious diseases
and bacteria on a daily basis. While the Company's CLO-D technology
is the premier effective all-natural biosafety solution which has
been proven 100% safe and not harmful to humans, there are no
assurances that the Company will be successful in developing or
exploiting such potential markets.
About Press Ventures
Press Ventures owns the worldwide rights to the patented Cedar
Leaf Oil Diffusion ("CLO-D") technology for the use of natural
non-human harming vapors to kill bacteria, mold, and viruses in
buildings. The patented CLO-D technology has been shown to be
capable of killing many deadly bacterial and viral substances such
as anthrax and H1N1 in buildings while they are still occupied. The
CLO-D technology has been laboratory and field tested and the
Company believes that use of the technology can provide a marked
improvement in air quality and eliminate many of the most dangerous
airborne bacteria, viruses, and pollutants. For additional
information about CLO-D technology and Press Ventures, please visit
www.biosafetysolutionsinc.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that
term is defined in Section 27(a) of the Securities Act of 1933, as
amended, and Section 21(e) of the Securities Exchange Act of 1934,
as amended. Statements in this press release that are not purely
historical are forward-looking statements and include any
statements regarding beliefs, plans, expectations or intentions
regarding the future. Such forward-looking statements include,
among other things, size and potential of the EU market for the
Company's products, global movement away from the use of harmful
chemicals, size and potential of the food processing facilities and
hospital biosafety markets for the Company's products demand for
natural biosafety solutions, exploitation of business
opportunities, target markets, strategic business goals, rise in
diseases, capability of the Company's technology and market
information. Actual results could differ from those projected
in any forward-looking statements due to numerous
factors. Such factors include, among others, the inherent
uncertainties associated with developing new products or
technologies and operating as a development stage company, our
ability to retain important members of our management team and
attract other qualified personnel, our ability to raise the
additional funding we will need to continue to pursue our business
and product development plans, our ability to develop and
commercialize products based on our technology platform, and market
conditions. These forward-looking statements are made as of
the date of this news release, and we assume no obligation to
update the forward-looking statements, or to update the reasons why
actual results could differ from those projected in the
forward-looking statements. Although we believe that any
beliefs, plans, expectations and intentions contained in this press
release are reasonable, there can be no assurance that any such
beliefs, plans, expectations or intentions will prove to be
accurate. Investors should consult all of the information set
forth herein and should also refer to the risk factors disclosure
outlined in the reports and other documents we file with the SEC,
available at www.sec.gov.
CONTACT: Investor Relations Contact:
1-888-709-1550
IR@kingstonir.net
Press Ventures (CE) (USOTC:PVEN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Press Ventures (CE) (USOTC:PVEN)
Historical Stock Chart
From Dec 2023 to Dec 2024